Bilateral Ovarian Removal Associated With Increased All-Cause Mortality


Woman who undergo bilateral removal of ovaries at the time of hysterectomy have higher risks of all-cause mortality afterward, including hospital admission for ischemic heart disease.

Woman who undergo bilateral removal of ovaries at the time of hysterectomy have higher risks of all-cause mortality afterward, according to a new study. Consistent with this finding, those women also had higher rates of hospital admission for ischemic heart disease, among other outcomes.

“Strong arguments exist to remove both ovaries at the time of hysterectomy in women who have reproductive cancers or who have a high risk of developing cancers,” wrote study authors led by Jemma Mytton, of University Hospitals Birmingham in the United Kingdom. “However, the lifetime risk of developing ovarian cancer is 1 in 52 in the United Kingdom, and the removal of a metabolically active organ such as the ovary may have harmful effects in the long term.”

The new study examined whether those potential effects have an impact on overall survival and other outcomes, using national databases of hospital admissions and deaths. In total, it included 113,679 patients aged 35 to 45 who underwent hysterectomy for benign conditions between April 2004 and March 2014. Of those, 37,098 patients (32.6%) underwent bilateral ovary removal. Results of the analysis were published online ahead of print last week in the British Medical Journal.

In the ovarian conservation group, the rate of hospital admission for ischemic heart disease was 1.60%, compared with 2.02% in the bilateral removal group, yielding an adjusted hazard ratio (HR) of 0.85 (95% CI, 0.77–0.93; P < .001). The median time to ischemic events was 56 months in the ovarian conservation patients, significantly longer than the 51 months in the bilateral removal group (P < .001).

Cancer admissions were also lower in the conservation group (2.80%) than in the bilateral removal group (3.49%), with an adjusted HR of 0.83 (95% CI, 0.78–0.89; P < .001).

The all-cause mortality rate in the ovarian conservation group was 0.60%, compared with 1.01% in the bilateral removal patients, for an adjusted HR of 0.64 (95% CI, 0.55–0.73; P < .001). More deaths in the conservation group (13.4%) occurred within the first 12 months following hysterectomy than in the bilateral removal group (17.3%), though this did not reach significance (P = .12). When the researchers excluded ovarian cancer deaths from this analysis, the adjusted HR was even more strongly in favor of conservation, at 0.60 (95% CI, 0.52–0.69; P < .01).

The authors wrote that these findings align with the theory that a drop in endogenous estrogen concentrations could increase heart disease risk. “We might expect the proportion of women who select bilateral ovarian removal to decline as the health risks that must be traded for a reduced incidence of ovarian cancer come into sharper focus,” they wrote.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content